Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas (original) (raw)
Ting AH et al. (2006) The cancer epigenome—components and functional correlates. Genes Dev20: 3215–3231 ArticleCASPubMed Google Scholar
Inche AG and La Thangue NB (2006) Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov Today11: 97–109 ArticleCASPubMed Google Scholar
Carey N and La Thangue NB (2006) Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol6: 369–375 ArticleCASPubMed Google Scholar
Marks P et al. (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer1: 194–202 ArticleCASPubMed Google Scholar
Marks PA and Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol25: 84–90 ArticleCASPubMed Google Scholar
Duvic M and Zhang C (2006) Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. Br J Cancer95: S13–S19 ArticleCASPubMed Central Google Scholar
Luger K et al. (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature389: 251–260 ArticleCASPubMed Google Scholar
Yoshida M et al. (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem265: 17174–17179 CASPubMed Google Scholar
Finnin MS et al. (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature401: 188–193 ArticleCASPubMed Google Scholar
Glaser KB et al. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther2: 151–163 CASPubMed Google Scholar
Johnstone RW and Licht JD (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell4: 13–18 ArticleCASPubMed Google Scholar
Mitsiades CS et al. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA101: 540–545 ArticleCASPubMed Google Scholar
Dokmanovic M et al. (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res5: 981–989 ArticleCASPubMed Google Scholar
Kovacs JJ et al. (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell18: 601–607 ArticleCASPubMed Google Scholar
Gu W and Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell90: 595–606 ArticleCASPubMed Google Scholar
Patel JH et al. (2004) The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol24: 10826–10834 ArticleCASPubMedPubMed Central Google Scholar
Billin AN et al. (2000) Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol Cell Biol20: 6882–6890 ArticleCASPubMedPubMed Central Google Scholar
Park JH et al. (2004) Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res10: 5271–5281 ArticleCASPubMed Google Scholar
Huang BH et al. (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ12: 395–404 ArticleCASPubMed Google Scholar
Kawaguchi Y et al. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell115: 727–738 ArticleCASPubMed Google Scholar
Vega K et al. (2004) Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell119: 555–566 ArticleCASPubMed Google Scholar
Arnold MA et al. (2007) MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev Cell12: 377–389 ArticleCASPubMed Google Scholar
Dequiedt F et al. (2003) HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity18: 687–698 ArticleCASPubMed Google Scholar
Zhu E et al. (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell5: 455–463 ArticleCASPubMed Google Scholar
Ropero S et al. (2006) A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet38: 566–569 ArticleCASPubMed Google Scholar
Minucci S and Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer6: 38–51 ArticleCASPubMed Google Scholar
Wu WS et al. (2001) The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol21: 2259–2268 ArticleCASPubMedPubMed Central Google Scholar
Reddy P et al. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukaemia effect. Proc Natl Acad Sci USA101: 3921–3926 ArticleCASPubMedPubMed Central Google Scholar
Brogdon JL et al. (2006) Histone deacetylase activities are required for innate immune cell control of Th1 but Th2 effector cell function. Blood109: 1123–1130 ArticlePubMedCAS Google Scholar
Tao R et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med13: 1299–1307 ArticleCASPubMed Google Scholar
Shao Y et al. (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA101: 18030–18035 ArticleCASPubMedPubMed Central Google Scholar
Yang X et al. (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res61: 7025–7029 CASPubMed Google Scholar
Ferrara FF et al. (2001) Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res61: 2–7 PubMed Google Scholar
Rahmani M et al. (2003) Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res63: 8420–8427 CASPubMed Google Scholar
Hideshima T et al. (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA102: 8567–8572 ArticleCASPubMedPubMed Central Google Scholar
Tumber A et al. (2007) The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol60: 275–283 ArticleCASPubMed Google Scholar
Marchion DC et al. (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem92: 223–237 ArticleCASPubMed Google Scholar
Glaser KB (2007) HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol74: 659–671 ArticleCASPubMed Google Scholar
Keehn CA et al. (2007) The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control14: 102–111 ArticlePubMed Google Scholar
Chuang TY et al. (1990) Incidence of cutaneous T cell lymphoma and other rare skin cancers in a defined population. J Am Acad Dermatol23: 254–256 ArticleCASPubMed Google Scholar
Willemze R et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood105: 3768–3785 ArticleCASPubMed Google Scholar
Lessin SR et al. (1994) Retroviruses and cutaneous T-cell lymphoma. Dermatol Clin12: 243–253 ArticleCASPubMed Google Scholar
Kim EJ et al. (2006) Mycosis fungoides and Sézary syndrome: an update. Curr Oncol Rep8: 376–386 ArticlePubMed Google Scholar
van Doorn R et al. (2002) A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res62: 5389–5392 CASPubMed Google Scholar
Sommer VH et al. (2004) In vivo activation of STAT3 in cutaneous T-cell lymphoma: evidence for an antiapoptotic function of STAT3. Leukemia18: 1288–1295 ArticleCASPubMed Google Scholar
Lauritzen AF et al. (1995) p53 protein expression in cutaneous T-cell lymphomas. Br J Dermatol133: 32–36 ArticleCASPubMed Google Scholar
Scarisbrick JJ et al. (2002) Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sézary syndrome. J Invest Dermatol118: 493–499 ArticleCASPubMed Google Scholar
Scarisbrick JJ et al. (2003) Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol121: 894–901 ArticleCASPubMed Google Scholar
Zhang C et al. (2007) Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sézary syndrome and role of the bmi-1 and ras oncogenes in disease progression. Hum Pathol38: 995–1002 ArticleCASPubMed Google Scholar
Sherr CJ and Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev13: 1501–1512 ArticleCASPubMed Google Scholar
van Doorn R et al. (2005) Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol23: 3886–3896 ArticleCASPubMed Google Scholar
Alizadeh AA et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature403: 503–511 ArticleCASPubMed Google Scholar
Martinez-Delgado B et al. (2002) Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int J Cancer102: 15–19 ArticleCASPubMed Google Scholar
Siu LL et al. (2003) Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br J Haematol122: 70–77 ArticleCASPubMed Google Scholar
Querfeld C et al. (2003) Primary cutaneous lymphomas: a review with current treatment options. Blood Rev17: 131–142 ArticlePubMed Google Scholar
Bunn PA Jr and Lamberg SI (1979) Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep63: 725–728 PubMed Google Scholar
Sausville EA et al. (1988) Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: definition of three distinctive prognostic groups. Ann Intern Med109: 372–382 ArticleCASPubMed Google Scholar
Trautinger F et al. (2006) EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer42: 1014–1030 ArticlePubMed Google Scholar
Budgin JB et al. (2005) Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol141: 315–321 ArticleCASPubMed Google Scholar
Zhang C et al. (2002) Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res8: 1234–1240 CASPubMed Google Scholar
Duvic M et al. (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol19: 2456–2471 ArticleCASPubMed Google Scholar
vanderSpek JC et al. (1993) Structure/function analysis of the transmembrane domain of DAB389-interleukin-2, an interleukin-2 receptor-targeted fusion toxin: the amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic domain to the cytosol of target cells. J Biol Chem268: 12077–12082 CASPubMed Google Scholar
Foss FM et al. (2001) Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma1: 298–302 ArticleCASPubMed Google Scholar
Olsen E et al. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol19: 376–388 ArticleCASPubMed Google Scholar
Mann BS et al. (2007) Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res13: 2318–2322 ArticleCASPubMed Google Scholar
Piekarz RL et al. (2001) Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood98: 2865–2868 ArticleCASPubMed Google Scholar
Kelly WK et al. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol23: 3923–3931 ArticleCASPubMed Google Scholar
O'Connor OA et al. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol24: 166–173 ArticleCASPubMed Google Scholar
Duvic M et al. (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood109: 31–39 ArticleCASPubMedPubMed Central Google Scholar
Olsen EA et al. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol25: 3109–3115 ArticleCASPubMed Google Scholar
Traynor AM et al. (2007) A phase II study of vorinostat (NSC 701852) in patients (pts) with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol25 (Suppl): 18044 Google Scholar
Galanis E et al. (2007) N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). J Clin Oncol25 (Suppl): 2004 Google Scholar
Hussain M et al. (2007) Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): A phase II trial by the Prostate Cancer Clinical Trials Consortium (NCI 6862). J Clin Oncol25 (Suppl): 5132 Google Scholar
Krug LM et al. (2006) Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer7: 257–261 ArticlePubMed Google Scholar
Piekarz R et al. (2007) Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. J Clin Oncol25 (Suppl): 8027 Google Scholar
Lerner A et al. (2006) Romidepsin (depsipeptide, FK228) induces clinically significant responses in treatment-refractory CTCL: interim report of a phase II multicenter study [abstract #2468]. Blood108: 699a Google Scholar
Parker C et al. (2007) Romidepsin (FK228), a histone deacetylase inhibitor: Final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol25 (Suppl): 15507 Google Scholar
Molife R et al. (2006) Phase II study of FK228 in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol24 (Suppl): 14554 Google Scholar
Sullivan D et al. (2006) A phase II study of PXD101 in advanced multiple myeloma [poster 3583]. Presented at the American Society of Hematology Annual Meeting: 2006 December 10–13, Orlando, FL
Prince M et al. (2006) LBH589, a novel deacetylase inhibitor (DACi), treatment of patients with cutaneous T cell lymphoma (CTCL): skin expression profiles in the first 24 h related to clinical response following therapy [abstract #2715]. Blood108 (ASH Meeting Abstracts)
Younes A et al. (2007) A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol25 (Suppl): 8000 Google Scholar
Methylgene (online 21 August 2007) Methylgene and Pharmion announce US orphan drug designation granted for mgcd0103 for the treatment of Hodgkin's lymphoma [http://www.methylgene.com/content.asp?node=267] (accessed 13 February 2008)
Zhang C et al. (2005) Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol125: 1045–1052 ArticleCASPubMed Google Scholar
Lee JH et al. (2006) Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther5: 3085–3095 ArticleCASPubMed Google Scholar
Zhou DC et al. (2002) Frequent mutations in the ligand-binding domain of PML-RAR alpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood99: 1356–1363 ArticleCASPubMed Google Scholar
Chung EJ et al. (2006) Assays for pharmacodynamic analysis of histone deacetylase inhibitors. Expert Opin Drug Metab Toxicol2: 213–230 ArticleCASPubMed Google Scholar